AEGiS-SFE: Blacks needed for HIV vaccine trials San Francisco ExaminerImportant note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Click here to return to Associated Press main menu
DonateNow
Print this Article


Blacks needed for HIV vaccine trials

San Francisco Examiner - February 12, 2004
Alison Soltau, Staff Writer


City health officials are appealing to reluctant African-Americans to take part in clinical trials for an HIV vaccine, in the hopes of curbing the epidemic among blacks, who show a high rate of infection for AIDS.

Recently, the federal government issued the San Francisco Black Coalition on AIDS a $20,000 grant to recruit black community members willing to test the new vaccine. But city officials are preaching to a community still mindful of the notorious Tuskegee syphilis study.

For 40 years, until 1972, the United States observed hundreds of black Alabama men, whom they knew were infected with syphilis, in order to record the progress of the disease.

The men thought they were being treated for their "bad blood," but researchers were doing nothing to treat the men's syphilis, even after penicillin had become available.

Because the experience of the Tuskegee travesty is still fresh, the black community has new worries about AIDS vaccine trials, according to Derrick Mapp, a community representative for The City's Department of Public Health.

"Their real concerns are, 'Are we going to be guinea pigs? I'm a healthy person, why would I want to stick something in me?'" Mapp said.

Health officials, however, stressed the importance of black involvement in testing vaccines, since researchers do not yet know if different ethnic groups respond differently to the HIV virus.

"We need to get over Tuskegee," said Gil Gerald, a member of the Black Coalition on AIDS. "If not enough of us are involved in research, it may not be conclusive about whether a vaccine is effective in our community."

Participants in testing the new vaccine will be given full details about the trial and its implications before they sign up, said Jennifer Sarche of the Department of Public Health.

She said that, so far, researchers had not seen any serious side effects in the trials, but, as with any medical research, there could be unknown risks.

"People know that when they sign up, but those who do chose to [participate anyway] have decided that it is the only way to try and stop this epidemic," Sarche said.

Troubling stats

African-Americans accounted for 19.5 percent or 57 new AIDS cases in San Francisco in 2003, but they make up only about 7.8 percent of The City's total population.

About 44 percent of the women infected with HIV in San Francisco are black women.


040212
SE040202


Copyright © 2004 - San Francisco Examiner. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the San Francisco Examiner, Permissions Desk, 110 Fifth Street, P.O. Box 7260, San Franciso, CA 94120.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .